Calcitonin gene-related peptide

Pain-sensing nerves and immune cells interact to worsen endometriosis in mice, suggesting CGRP-inhibiting drugs used for migraines could treat the disorder. Current treatments are limited, and endometriosis research is underfunded.

Lundbeck's Vyepti® (eptinezumab) met primary and secondary endpoints in phase III SUNRISE trial, showing significant reductions in monthly migraine days and early preventive effects, with plans to discuss regulatory approval for Asian markets.

Click Therapeutics, a software as a medical device biotech company, focuses on creating digital medicines to address cognitive deficits in the brain. The company operates a hybrid model with global pharma partnerships and internal FDA-approved assets. Click's approach is data-driven, aiming to achieve drug-like outcomes and disrupt existing drug classes. The company's strategy pivoted towards partnerships during market downturns, preserving capital and scaling the business. Click's digital drugs, like those for migraine, aim to complement existing therapies and improve patient outcomes. The FDA's PDURS guidance is seen as a game changer, potentially accelerating the digital therapeutics market by creating a pathway for combining digital drugs with traditional drugs in clinical trials.

Migraine clinical trials research has increased from 2004-2023, analyzed via CiteSpace and VOSviewer, identifying the U.S. and Albert Einstein College of Medicine as leaders. Migraine, characterized by severe headaches and associated symptoms, remains a chronic issue despite drug availability.

Rimegepant (Nurtec ODT) is a CGRP receptor antagonist approved for acute and preventive migraine treatment. A pooled analysis of 4 trials showed rimegepant 75 mg outperformed placebo in pain freedom and symptom relief at 2 hours, with low adverse events. Early intervention, consistent use, and flexibility in treatment optimize rimegepant's effectiveness. Reduced rescue medication use suggests lower risk of medication overuse headache. CGRP-targeting treatments are increasingly recommended as first-line for migraine management.

A study reveals *ubrogepant* (brand name *Uberlevi*) may prevent migraines if taken at pre-migraine symptoms, with 65% reporting minimal pain 24 hours later. The drug targets CGRP protein, offering potential for proactive migraine management.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

Sanofi's phase 3 HERCULES study of tolebrutinib met primary endpoint of reducing disability in non-relapsing secondary progressive multiple sclerosis (nrSPMS). Roche's fenebrutinib showed significant relapse suppression in relapsing MS without disability change. FDA accepted Axsome Therapeutics' resubmitted NDA for AXS-07 for acute migraine treatment.